Genentech, Inc.

University of Texas System

Craig W Crowley

Leonard G Presta

Henry Bernard Lowman

Robert S McDowell

Joseph L Goldstein

Michael S Brown

Camellia W Adams

Gerald R Nakamura

Todd C Somers

James C Marsters

Guy L James

Victoria Smith

Dan L Eaton

Andrew G Polson

David A Oare

Mark E Reynolds

Thomas E Rawson

Andrew C Chan

Frederic J De Sauvage

Allen J Ebens

Leonard Presta

Andrew Poison

Frederic J DeSauvage

Frederic J Desauvage

Allen Jr Ebens

Frederic Desauvage

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Compositions and methods for the treatment of tumor of hematopoietic origin

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

Ras farnesyl transferase inhibitors

A method for selecting recombinant host cells expressing high levels of a desired protein is described. This method utilizes eukaryotic host cells harboring a DNA construct comprising a selectable gene (preferably an amplifiable gene) and a product gene provided 3' to the selectable gene. The selectable gene is positioned within an intron defined by a splice donor site and a splice acceptor site and the selectable gene and product gene are under the transcriptional control of a single transcriptional regulatory region. The splice donor site is generally an efficient splice donor site and thereby regulates expression of the product gene using the transcriptional regulatory region. The transfected cells are cultured so as to express the gene encoding the product in a selective medium comprising an amplifying agent for sufficient time to allow amplification to occur, whereupon either the desired product is recovered or cells having multiple copies of the product gene are identified.

Method for selecting high-expressing host cells

Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated. Also disclosed are benzazepines of the following general formula (II) having similar utility as the aforementioned benzodiazepines: ##STR1##

Growing community of inventors

Portola Valley, CA, United States of America

Craig W Crowley